Article
Urology & Nephrology
Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, Carina Bernardo, Gunilla Chebil, Pontus Eriksson, Iva Johansson, Petter Kollberg, Claes Lindh, Kristina Lovgren, Nour-al-Dain Marzouka, Hans Olsson, Mattias Hoglund, Anders Ullen, Fredrik Liedberg
Summary: This study investigates the impact of molecular subtypes on pathological response and survival in patients with muscle-invasive bladder cancer (MIBC) receiving preoperative cisplatin-based chemotherapy. The results suggest that patients with certain molecular subtypes, such as genomically unstable (GU) and urothelial-like (Uro) tumors, are more responsive to cisplatin-based neoadjuvant chemotherapy and have improved survival compared to those with the basal/squamous (Ba/Sq) subtype. The study highlights the potential of subtype-specific biomarkers, such as osteopontin (SPP1), for developing a more precision-based treatment approach for neoadjuvant chemotherapy in MIBC.
Article
Biochemistry & Molecular Biology
Montserrat Justo-Garrido, Alejandro Lopez-Saavedra, Nicolas Alcaraz, Carlo C. Cortes-Gonzalez, Luis F. Onate-Ocana, Claudia Haydee Sarai Caro-Sanchez, Clementina Castro-Hernandez, Cristian Arriaga-Canon, Jose Diaz-Chavez, Luis A. Herrera
Summary: Chemoresistance to standard neoadjuvant treatment is common in locally advanced breast cancer, particularly in the luminal subtype. Identifying genes associated with chemoresistance is crucial for understanding mechanisms and finding effective treatments. This study aimed to identify genes linked to neoadjuvant chemotherapy resistance in patients with luminal breast cancer. Whole RNA sequencing of patient biopsies revealed 269 differentially expressed genes in chemoresistant patients and validated eight highly correlated genes. SLC12A1 and GRIA4, both involved in ion transport, showed the strongest association with chemoresistance. Findings suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Giuseppe Basile, Marco Bandini, Ewan A. Gibb, Jeffrey S. Ross, Daniele Raggi, Laura Marandino, Tiago Costa de Padua, Emanuele Crupi, Renzo Colombo, Maurizio Colecchia, Roberta Lucian, Luigi Nocera, Marco Moschini, Alberto Briganti, Francesco Montorsi, Andrea Necchi
Summary: The PURE-01 study confirms the sustained efficacy of neoadjuvant immune-checkpoint inhibitor therapy in patients with muscle-invasive urothelial bladder carcinoma (MIBC). PD-L1 expression is the strongest predictor of sustained response post-RC.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sarah M. H. Einerhand, Nick van Dijk, Jeroen van Dorp, Jeantine M. de Feijter, Maurits L. van Montfoort, Maaike W. van de Kamp, Eva E. Schaake, Thierry N. Boellaard, Kees Hendricksen, Michiel S. van der Heijden, Bas W. G. van Rhijn
Summary: This study compared the clinical outcomes of neoadjuvant/induction platinum-based combination chemotherapy (NAIC) with combination immune checkpoint inhibition (cICI) in patients with locally advanced urothelial carcinoma. The results showed that cICI was associated with superior progression-free survival and overall survival compared to NAIC. This provides a strong rationale for validating cICI as the standard treatment for locally advanced urothelial carcinoma.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Surgery
Patrick M. Collins, Micheal J. Brennan, Jessie A. Elliott, Sami Abd Elwahab, Kevin Barry, Karl Sweeney, Carmel Malone, Aoife Lowery, Ray Mclaughlin, Michael J. Kerin
Summary: In ER/PR positive, HER2 negative breast cancer patients receiving NAC, the pCR rates are low. Patients with high tumor grade and weak PR expression show the most promising response rates. The 5-year invasive disease-free survival rate and overall survival rate are relatively good.
AMERICAN JOURNAL OF SURGERY
(2021)
Letter
Medicine, General & Internal
Tawee Tanvetyanon
Summary: This article reports that neoadjuvant treatment with nivolumab does not impede the feasibility of lung cancer surgery, but some patients had their surgeries canceled due to disease progression after treatment, which is concerning as they could have been cured through surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Vladimir O. O. Sigin, Alexey I. I. Kalinkin, Alexandra F. F. Nikolaeva, Ekaterina O. O. Ignatova, Ekaterina B. B. Kuznetsova, Galina G. G. Chesnokova, Nikolai V. V. Litviakov, Matvey M. M. Tsyganov, Marina K. K. Ibragimova, Ilya I. I. Vinogradov, Maxim I. I. Vinogradov, Igor Y. Y. Vinogradov, Dmitry V. V. Zaletaev, Marina V. V. Nemtsova, Sergey I. I. Kutsev, Alexander S. S. Tanas, Vladimir V. V. Strelnikov
Summary: Breast cancer is a heterogeneous disease with various morphologies, progressions, survival rates, and responses to therapy. There is a lack of molecular markers to predict its response to neoadjuvant chemotherapy. In this study, we performed genome-wide DNA methylation screening of tumors in NACT responders and nonresponders to identify epigenomic markers. We proposed diagnostic panels that can be easily implemented in diagnostic laboratories and combined them with clinical characteristics for improved prediction accuracy.
Article
Medicine, General & Internal
Thomas F. Monaghan, Dennis J. Robins, Nicholas R. Suss, Connelly D. Miller, Viktor X. Flores, Matthew T. Smith, Jeffrey P. Weiss, Brian K. McNeil, Andrew G. Winer
Summary: The study identified that age, disease severity, cancer stage, income, distance to treatment center, treatment in certain programs, and year of diagnosis were independent predictors of receiving neoadjuvant chemotherapy in bladder cancer patients. Access to transportation and social resources also impact the likelihood of receiving neoadjuvant chemotherapy.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Oncology
Mike Wenzel, Marina Deuker, Luigi Nocera, Claudia Colla Ruvolo, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Andreas Becker, Luis A. Kluth, Felix K. H. Chun, Pierre Karakiewicz
Summary: Variant histology in urethral cancer is associated with higher cancer specific mortality compared to urothelial histology. Chemotherapy improves survival in metastatic urethral cancer patients with adenocarcinoma and other variant histology, but not in those with squamous cell carcinoma.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
David Oswald, Maximilian Pallauf, Susanne Deininger, Peter Torzsok, Manuela Sieberer, Christian Eiben
Summary: This study analyzed the effectiveness of neoadjuvant chemotherapy and immunotherapy in patients with upper tract urothelial carcinoma. The results showed that neoadjuvant chemotherapy significantly improved pathological downstaging and complete response rates, as well as overall survival and progression-free survival. However, there were no comparative studies on immunotherapy in this setting.
Article
Biochemistry & Molecular Biology
Zi Wang, Bircan Coban, Chen-Yi Liao, Yao-Jun Chen, Qiuyu Liu, Erik H. J. Danen
Summary: GRHL2 has different roles in different breast cancer subtypes, promoting cancer growth in some subtypes and suppressing cancer progression in others. Its expression is increased in all subtypes of breast cancer and inversely correlated with overall survival in basal-like breast cancer patients. GRHL2 regulates cell-cell junction, epithelial migration, and proliferation in both luminal and basal A breast cancer subtypes, but has distinct effects on cell cycle arrest and migration in these subtypes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Antonino Grassadonia, Vincenzo Graziano, Laura Iezzi, Patrizia Vici, Maddalena Barba, Laura Pizzuti, Giuseppe Cicero, Eriseld Krasniqi, Marco Mazzotta, Daniele Marinelli, Antonella Amodio, Clara Natoli, Nicola Tinari
Summary: The study found that in patients with luminal breast cancer receiving neoadjuvant chemotherapy, pre-treatment NLRlow was significantly associated with shorter DFS and OS. Additionally, non-ductal histology, luminal B subtype, and post-treatment Ki67 >= 14% were also associated with worse DFS.
Article
Multidisciplinary Sciences
Barak Rosenzweig, Renato B. Corradi, Sadna Budhu, Ricardo Alvim, Pedro Recabal, Stephen La Rosa, Alex Somma, Sebastien Monette, Avigdor Scherz, Kwanghee Kim, Jonathan A. Coleman
Summary: The study demonstrated that neoadjuvant sub-ablative vascular-targeted photodynamic therapy delayed local and systemic progression, prolonged progression-free and overall survival, and reduced local recurrence in a murine model of urothelial cancer, showing therapeutic efficacy through an immune-mediated response.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Elise F. Nassif, Bernhard Mlecnik, Constance Thibault, Marie Auvray, Daniela Bruni, Alexandre Colau, Eva Comperat, Gabriela Bindea, Aurelie Catteau, Aurelie Fugon, Isabelle Boquet, Marine Martel, Philippe Camparo, Pierre Colin, Roubini Zakopoulou, Aristotelis Bamias, Mostefa Bennamoun, Xavier Barthere, Bruno D'acremont, Marine Lefevre, Francois Audenet, Arnaud Mejean, Virginie Verkarre, Stephane Oudard, Jerome Galon
Summary: The study demonstrated the significant prognostic and predictive roles of the Immunoscore in localized muscle-invasive bladder cancer patients, aiding in predicting patient response to neoadjuvant chemotherapy and survival outcomes.
Article
Oncology
Shirong Tan, Xin Fu, Shouping Xu, Pengfei Qiu, Zhidong Lv, Yingying Xu, Qiang Zhang
Summary: This study aimed to quantify changes in Ki67 proliferation before and after neoadjuvant chemotherapy, establish an optimal cut-off point, and evaluate its predictive value for survival outcomes in different molecular subtypes of breast cancer. Results showed significant effects between pathological complete response and survival outcomes in HER2-enriched and triple-negative breast cancer, while a decrease in Ki67 was confirmed post-chemotherapy. The Delta Ki67% was identified as a significant independent prognostic factor for patients with Luminal B and triple-negative breast cancer.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Article
Urology & Nephrology
Maria Carmen Mir, Michele Marchioni, Homi Zargar, K. Zargar-Shoshtari, A. S. Fairey, Laura S. Mertens, C. P. Dinney, L. M. Krabbe, M. S. Cookson, N. E. Jacobsen, J. Griffin, J. S. Montgomery, N. Vasdev, E. Y. Yu, E. Xylinas, J. S. McGrath, W. Kassouf, M. A. Dall'Era, S. S. Sridhar, J. Aning, S. F. Shariat, J. L. Wright, A. C. Thorpe, T. M. Morgan, J. M. Holzbeierlein, T. J. Bivalacqua, S. North, D. A. Barocas, Y. Lotan, P. Grivas, A. J. Stephenson, J. B. Shah, B. W. van Rhijn, P. E. Spiess, D. Daneshmand, P. C. Black
Summary: A postoperative nomogram for predicting bladder cancer-specific mortality (BCSM) in MIBC patients was developed using international consortium data, with pathological stage, lymph node metastasis, and positive surgical margins identified as significant factors associated with BCSM. The model showed modest net benefit and clinical utility, providing key insights for patient counseling and high-risk patient identification for clinical trials.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Multidisciplinary Sciences
Guoliang Yang, Jolanta Bondaruk, David Cogdell, Ziqiao Wang, Sangkyou Lee, June Goo Lee, Shizhen Zhang, Woonyoung Choi, Yan Wang, Yu Liang, Gang Wang, Ying Wang, Hui Yao, Vipulkumar Dadhania, Jianjun Gao, Christopher Logothetis, Arlene Siefker-Radtke, Ashish Kamat, Colin Dinney, Dan Theodorescu, Marek Kimmel, Peng Wei, Charles C. Guo, John N. Weinstein, David J. McConkey, Bogdan Czerniak
Editorial Material
Urology & Nephrology
Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke
Article
Biochemistry & Molecular Biology
Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene Siefker-Radtke, Matthew T. Campbell, Rebecca Slack Tidwell, Charles C. Guo, Ashish M. Kamat, Surena F. Matin, John C. Araujo, Amishi Y. Shah, Pavlos Msaouel, Paul Corn, Jianbo Wang, John N. Papadopoulos, Shalini S. Yadav, Jorge M. Blando, Fei Duan, Sreyashi Basu, Wenbin Liu, Yu Shen, Yuwei Zhang, Marc Daniel Macaluso, Ying Wang, Jianfeng Chen, Jianhua Zhang, Andrew Futreal, Colin Dinney, James P. Allison, Sangeeta Goswami, Padmanee Sharma
Article
Urology & Nephrology
Kelly K. Bree, Patrick J. Hensley, Nathan A. Brooks, Justin Matulay, Roger Li, Graciela M. Nogueras Gonzalez, Neema Navai, Herbert Barton Grossman, Surena F. Matin, Colin P. N. Dinney, Ashish M. Kamat
Summary: Patients with UTUC prior to NMIBC diagnosis had higher rates of recurrence and progression after adequate BCG therapy, with high-grade UTUC-P associated with increased NMIBC recurrence.
Article
Urology & Nephrology
Nathan A. Brooks, Andrea Kokorovic, Lianchen Xiao, Justin T. Matulay, Roger Li, Weranja K. B. Ranisinghe, Supriya Nagaraju, Yu Shen, Jianjun Gao, Neema Navai, Colin P. N. Dinney, H. Barton Grossman, Ashish M. Kamat
Summary: The obesity paradox may be present in patients receiving bacillus Calmette-Guerin (BCG) treatment for non-muscle-invasive bladder cancer, with overweight and obese patients showing improved outcomes but those with diabetes mellitus at increased risk of recurrence.
Article
Oncology
Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne K. Schuckman, Tracy M. Downs, Robert S. Svatek, Joseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael E. Woods, Gordon Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O'Donnell, David Sawutz, Richard Philipson, Ruth Coll, Vikram M. Narayan, F. Peter Treasure, Seppo Yla-Herttuala, Nigel R. Parker, Colin P. N. Dinney
Summary: The study demonstrates the efficacy of intravesical nadofaragene firadenovec, a novel therapy using a replication-deficient recombinant adenovirus, in patients with BCG-unresponsive non-muscle-invasive bladder cancer, with a favorable benefit:risk ratio. The treatment led to a complete response in a significant proportion of patients with carcinoma in situ, and the adverse events were generally mild, with no treatment-related deaths reported.
Article
Oncology
Janet Baack Kukreja, Mohamed A. Seif, Marissa W. Mery, James R. Incalcaterra, Ashish M. Kamat, Colin P. Dinney, Jay B. Shah, Thomas W. Feeley, Neema Navai
Summary: Using Time-Driven Activity-Based Costing (TDABC), this study identified inpatient care as the major cost driver in radical cystectomy, followed closely by operating room costs and readmission expenses. Efforts to reduce costs in radical cystectomy should be focused on these areas.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Urology & Nephrology
Justin T. Matulay, Roger Li, Patrick J. Hensley, Nathan A. Brooks, Vikram M. Narayan, H. Barton Grossman, Neema Navai, Colin P. N. Dinney, Ashish M. Kamat
Summary: The study retrospectively reviewed data of patients with nonmuscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guerin at a tertiary cancer center. Results showed that these patients had improved survival and progression rates compared to previous studies, providing valuable benchmarks for clinical trial design.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Gang Wang, Peter C. Black, Peter J. Goebell, Lingyun Ji, Carlos Cordon-Cardo, Bernd Schmitz-Draeger, Debra Hawes, Bogdan Czerniak, Sarah Minner, Guido Sauter, Frederic Waldman, Susan Groshen, Richard J. Cote, Colin P. Dinney
Summary: The study evaluated the prognostic value of 10 putative tumor markers in locally advanced urothelial cancer of the bladder through immunohistochemistry, finding that altered expression of p53, Rb, and p21 was associated with worse outcome. However, there was poor overall agreement in IHC scoring among laboratories and a lack of clear association between the markers and prognosis.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Urology & Nephrology
Patrick J. Hensley, Kelly K. Bree, Nathan Brooks, Justin Matulay, Roger Li, Graciela M. Nogueras Gonzalez, Neema Navai, Herbert B. Grossman, Colin P. Dinney, Ashish M. Kamat
Summary: The timing of induction BCG instillation after TURBT does not influence the tolerability and response rates in patients with NMIBC. Early administration of BCG is safe and delays do not impact therapeutic outcomes.
Article
Oncology
A. S. Feils, A. K. Erbe, J. Birstler, K. Kim, U. Hoch, S. L. Currie, T. Nguyen, D. Yu, A. O. Siefker-Radtke, N. Tannir, S. M. Tolaney, A. Diab, P. M. Sondel
Summary: In a retrospective analysis of the PIVOT-02 trial, it was found that patients with inhibitory KIR2DL2 and its ligand (HLA-C1) had better clinical outcomes when treated with BEMPEG and nivolumab, including greater tumor shrinkage, increased progression-free survival (PFS), and improved overall response rate (OR). Furthermore, patients with both inhibitory KIR2DL2 and its ligand and inhibitory KIR3DL1 and its ligand (HLA-Bw4) showed even better clinical outcomes compared to patients with complementary genotypes. FC gamma R polymorphisms did not affect clinical outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Oncology
Come Tholomier, Alberto Martini, Sharada Mokkapati, Colin P. Dinney
Summary: Gene therapy aims to alter cell properties through nucleotide delivery for disease treatment. Originally developed for genetic disorders, current research focuses on gene therapy strategies for bladder cancer.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Editorial Material
Oncology
Arlene O. Siefker-Radtke, Diana Cauley, Omar Alhalabi
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
David D'Andrea, Surena Matin, Peter C. Black, Firas G. Petros, Homayoun Zargar, Colin P. Dinney, Michael S. Cookson, Wassim Kassouf, Marc A. Dall'Era, John S. McGrath, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeffrey M. Holzbeierlein, Trinity J. Bivalacqua, Srikala S. Sridhar, Scott North, Daniel A. Barocas, Yair Lotan, Andrew J. Stephenson, Bas W. van Rhijn, Philippe E. Spiess, Siamak Daneshmand, Shahrokh F. Shariat
Summary: The study found that patients with UTUC had a lower rate of pathological complete response but a higher rate of pathological objective response after NAC treatment. Cox regression analysis revealed that UTUC patients had better overall survival and cancer-specific survival outcomes.
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
